Immatics N.V. IMTX
6.17 USD 0.00 (+0.00%)
Regular-session close
6.50 +0.33 +5.35%
Pre-market · Nov 17, 9:06 AM ET
6.07 Day range 6.57
6.07 52-week range 12.41
- YTD
- -41.24%
- 1 year
- -39.51%
News
benzinga.com Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients - Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a…
zacks.com Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.benzinga.com Immatics Q3 EPS $(0.58) Misses $(0.49) Estimate, Sales $7.968M Miss $10.230M Estimate Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.49) by 18.37 percent. This is a 18.37 percent decrease over losses of $(0.49)…
globenewswire.com Immatics Announces Third Quarter 2026 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…benzinga.com Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and…
